gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TARSHealthcareBiotechnology

Tarsus Pharmaceuticals, Inc. Common Stock (TARS)

$69.07−4.91%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$72.64▲ 4.08% in range
Nov 3, 2025Low $56.11 · High $90.78Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Tarsus Pharmaceuticals closed at $69.07 on Nov 4, down 4.91%, 23.9% below its 52-week closing high. Volume of 2.6M shares was 2.80× its 20-day average (well above normal).

Split-adjusted performance: -6.8% over one month, +6.7% over six months, -1.0% over one year.

In the quarter ended Sep 30, 2026, revenue was $194.57M, up 63.9% from a year earlier, with a net margin of -343.5%.

Short interest was 5.7M shares at the Oct 15 settlement, down 5.6% from the prior report (15.3% of float, 5.7 days to cover).

Market cap$3.23B46.8M shares
Revenue · quarter$194.6M+63.9% YoY
Diluted EPS$-14.40—
P/E · TTM—P/S 4.7×
Net margin-343.5%Gross 92.9%
Dividend yieldNone
52-week range56.11 – 90.78−23.9% from high
Volume2.6M2.80× 20-day avg
Volatility · 60d47.0%Annualised
Short % of float15.3%5.7 days to cover
Net cash$236.7MCash $309.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.1%1M −6.8%3M +5.7%6M +6.7%YTD −15.6%1Y −1.0%3Y +389.2%5Y +150.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum71
Revenue growth79
Net margin48
Value (low P/E)—
Size83

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short5.7M−5.6% vs prior
Days to cover5.7Settled Oct 15
% of float15.3%
Short vol. 10d70.9%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TARSTarsus Pharmaceuticals$69.07−4.91%+6.7%+63.9%−343.5%—$3.23B
DNLIDenali Therapeutics$20.96+7.76%+2.7%—−3539.2%—$3.35BCompare
BEAMBeam Therapeutics$27.79+5.54%−14.1%−94.2%−25036.3%—$2.87BCompare
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94BCompare
RLAYRelay Therapeutics$18.03+3.38%+39.6%−48.3%−23916.3%—$3.95BCompare
ADPTAdaptive Biotechnologies$26.71+3.53%+85.1%+21.5%−55.6%—$4.26BCompare
ADMAADMA Biologics$10.48−5.67%+4.0%+2.0%30.4%13.9$2.35BCompare
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32BCompare

News about Tarsus Pharmaceuticals

All news →
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 1d ago▲ PositiveHow Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%Zacks Investment Research · 2d ago▲ PositiveEarnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineZacks Investment Research · Oct 27, 2026▼ NegativeTarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026GlobeNewswire Inc. · Aug 6, 2026NeutralTarsus to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · May 7, 2026▲ Positive

Quick answers

What does Tarsus Pharmaceuticals do?
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions.
What is TARS's market cap?
$3.23B, based on the Nov 4 close of $69.07.
Does Tarsus Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TARS is sold short?
5.7M shares, 15.3% of float, as of Oct 15, 2026.
What sector is TARS in?
Healthcare, in the Biotechnology industry.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

HQ: Irvine, CA370 employeesListed Oct 16, 2020tarsusrx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology